Role of 14-3-3 protein and oxidative stress in diabetic cardiomyopathy

Acta Physiologica Hungarica

Volumn 96, Issue 3, 2009, Pages 277-287

  Watanabe, K ^a   Thandavarayan, R A ^a   Gurusamy, N ^b   Zhang, S ^c   Muslin, A J ^d   Suzuki, K ^e   Tachikawa, H ^e   Kodama, M ^e   Aizawa, Y ^e  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c Lightlab Imaging Inc   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

14 3 3 protein; Apoptosis; Cardiomyopathy; Diabetes mellitus; Glycogen synthase kinase 3 beta; Hypertrophy; Mitogen activated protein kinase; Oxidative stress; Protein kinase C

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; PROTEIN 14 3 3;

APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; DISEASE EXACERBATION; HEART DISEASE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; CARDIOMYOPATHY; FIBROSIS; METABOLISM; PATHOLOGY;

14-3-3 PROTEINS; ANGIOTENSIN II; ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; FIBROSIS; HUMANS; MYOCARDIUM; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 70349782671     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.96.2009.3.3     Document Type: Review

References (75)

1. Aitken A, Howell S, Jones D, Madrazo J, Martin H, Patel Y, Robinson K: Post-translationally modified 14-3-3 isoforms and inhibition of protein kinase C. Mol. Cell. Biochem. 149-150, 41-49 (1995)
2. Alici B, Gumustas MK, Ozkara H, Akkus E, Demirel G, Yencilek F, Hattat H: Apoptosis in the erectile tissues of diabetic and healthy rats. BJU Int. 85, 326-329 (2000)
3. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40, 405-412 (1991)
4. Bonow RO, Gheorghiade M: The diabetes epidemic: a national and global crisis. Am. J. Med. 116 Suppl 5A, 2S-10S (2004)
5. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625 (2005)
6. Cai L, Chen S, Evans T, Deng DX, Mukherjee K, Chakrabarti S: Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism. Urol. Res. 28, 342-347 (2000)
7. Cai L, Kang YJ: Cell death and diabetic cardiomyopathy. Cardiovasc. Toxicol. 3, 219-228 (2003)
8. Cai L, Kang YJ: Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 1, 181-193 (2001)
9. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ: Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51, 1938-1948 (2002)
10. Campbell SE, Katwa LC: Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J. Mol. Cell. Cardiol. 29, 1947-1958 (1997)
11. Clerk A, Bogoyevitch MA, Anderson MB, Sugden PH: Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogenactivated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J. Biol. Chem. 269, 32848-32857 (1994)
12. Cook SA, Sugden PH, Clerk A: Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J. Mol. Cell. Cardiol. 31, 1429-1434 (1999)
13. Decock JB, Gillespie-Brown J, Parker PJ, Sugden PH, Fuller SJ: Classical, novel and atypical isoforms of PKC stimulate ANF- and TRE/AP-1-regulated- promoter activity in ventricular cardiomyocytes. FEBS Lett. 356, 275-278 (1994)
14. Diwan A, Tran T, Misra A, Mann DL: Inflammatory mediators and the failing heart: a translational approach. Curr. Mol. Med. 3, 161-182 (2003)
15. Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R: Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol. Pharmacol. 67, 1237-1246 (2005)
16. Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567 (2004)
17. Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR: Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 48, 881-889 (1999)
18. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP: A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100, 1226-1231 (2003)
19. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab. Invest. 80, 513-527 (2000)
20. Francis GS: Diabetic cardiomyopathy: fact or fiction? Heart 85, 247-248 (2001)
21. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P: Myocardial cell death in human diabetes. Circ. Res. 87, 1123-1132 (2000)
22. Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647 (2000)
23. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19, 257-267 (1996)
24. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS: Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 40, 352-363 (1998)
25. Grimm D, Jabusch HC, Kossmehl P, Huber M, Fredersdorf S, Griese DP, Kramer BK, Kromer EP: Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade. Cardiovasc. Pathol. 11, 229-237 (2002)
26. Gurusamy N, Watanabe K, Ma M, Prakash P, Hirabayashi K, Zhang S, Muslin AJ, Kodama M, Aizawa Y: Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol. FEBS Lett. 580, 1932-1940 (2006)
27. Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M, Aizawa Y: Dominant negative 14-3- 3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem. Biophys. Res. Commun. 320, 773-780 (2004)
28. Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M, Aizawa Y: Inactivation of 14-3-3 protein exacerbates cardiac hypertrophy and fibrosis through enhanced expression of protein kinase C beta 2 in experimental diabetes. Biol. Pharm. Bull. 28, 957-962 (2005)
29. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46, 847-853 (1997) (Pubitemid 27188263)
30. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY: High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 101, 2618-2624 (2000)
31. Hoenack C, Roesen P: Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes 45 Suppl 1, S82-S87 (1996)
32. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J. Am. Soc. Nephrol. 14, S227-S232 (2003)
33. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P: IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50, 1414-1424 (2001)
34. Kang YJ: Molecular and cellular mechanisms of cardiotoxicity. Environ. Health Perspect. 109 Suppl 1, 27-34 (2001)
35. Kim S, Wanibuchi H, Hamaguchi A, Miura K, Yamanaka S, Iwao H: Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 30, 1054-1061 (1997)
36. Kralik PM, Ye G, Metreveli NS, Shem X, Epstein PN: Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovasc. Toxicol. 5, 285-292 (2005)
37. Kupfahl C, Pink D, Friedrich K, Zurbrugg HR, Neuss M, Warnecke C, Fielitz J, Graf K, Fleck E, Regitz-Zagrosek V: Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc. Res. 46, 463-475 (2000)
38. Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens. 22, 2253-2261 (2004)
39. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z: Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin. Sci. (Lond). 104, 341-347 (2003)
40. Lee JC, Downing SE: Ventricular performance in diabetic rabbits with norepinephrine cardiomyopathy. Proc. Soc. Exp. Biol. Med. 181, 345-350 (1986)
41. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, Das DK, Tosaki A: Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 294, H859-H866 (2008)
42. Li X, Xu Z, Li S, Rozanski GJ: Redox regulation of Ito remodeling in diabetic rat heart. Am. J. Physiol. Heart Circ. Physiol. 288, H1417-H1424 (2005)
43. Liao W, Wang S, Han C, Zhang Y: 14-3-3 proteins regulate glycogen synthase 3beta phosphorylation and inhibit cardiomyocyte hypertrophy. FEBS J. 272, 1845-1854 (2005)
44. Ligeti L, Szenczi O, Prestia CM, Szabo C, Horvath K, Marcsek ZL, van Stiphout RG, van Riel NA, Op den Buijs J, Van der Vusse GJ, Ivanics T: Altered calcium handling is an early sign of streptozotocininduced diabetic cardiomyopathy. Int. J. Mol. Med. 17, 1035-1043 (2006)
45. Liu W, Schoenkerman A, Lowe WL Jr.: Activation of members of the mitogen-activated protein kinase family by glucose in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 279, E782-E790 (2000)
46. Lorell BH, Carabello BA: Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102, 470-490 (2000)
47. Machackova J, Liu X, Lukas A, Dhalla NS: Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol. Cell. Biochem. 261, 271-278 (2004)
48. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 173, 932-939 (1990)
49. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790 (2000)
50. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R: Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1, 43-47 (1985)
51. Pang Y, Hunton DL, Bounelis P, Marchase RB: Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 51, 3461-3467 (2002)
52. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN: CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105, 1395-1406 (2000)
53. Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Maulik G, Bagchi M, Bagchi D, Maulik N: Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim. Biophys. Acta 1792, 39-48 (2009)
54. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, Morrice N, Mackintosh C: 14-3- 3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem. J. 379, 395-408 (2004)
55. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J: AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42, 206-212 (2003)
56. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923 (1996)
57. Roberts MR: Regulatory 14-3-3 protein-protein interactions in plant cells. Curr. Opin. Plant Biol. 3, 400-405 (2000)
58. Robinson K, Jones D, Patel Y, Martin H, Madrazo J, Martin S, Howell S, Elmore M, Finnen MJ, Aitken A: Mechanism of inhibition of protein kinase C by 14-3-3 isoforms. 14-3-3 isoforms do not have phospholipase A2 activity. Biochem. J. 299 (Pt 3), 853-861 (1994)
59. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, Okada Y, Nakanishi I: Collagen remodelling in myocardia of patients with diabetes. J. Clin. Pathol. 46, 32-36 (1993)
60. Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J. Mol. Med. 76, 725-746 (1998)
61. Szendrei L, Turoczi T, Kovacs P, Vecsernyes M, Das DK, Tosaki A: Mitochondrial gene expression and ventricular fibrillation in ischemic/reperfused nondiabetic and diabetic myocardium. Biochem. Pharmacol. 63, 543-552 (2002)
62. Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, Zhang S, Muslin AJ, Kodama M, Aizawa Y: 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem. Pharmacol. 75, 1797-1806 (2008)
63. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, Maulik N: Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 43, 720-729 (2007)
64. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A: Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32, 273-279 (1998)
65. Tomita M, Mukae S, Geshi E, Umetsu K, Nakatani M, Katagiri T: Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat heart. Jpn. Circ. J. 60, 673-682 (1996)
66. Tosaki A, Pali T, Droy-Lefaix MT: Effects of Ginkgo biloba extract and preconditioning on the diabetic rat myocardium. Diabetologia 39, 1255-1262 (1996)
67. Tzivion G, Shen YH, Zhu J: 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene 20, 6331-6338 (2001)
68. van Hemert MJ, Steensma HY, van Heusden GP: 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 23, 936-946 (2001)
69. Wang W, Shakes DC: Molecular evolution of the 14-3-3 protein family. J. Mol. Evol. 43, 384-398 (1996)
70. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51, 2709-2718 (2002)
71. Wilker E, Yaffe MB: 14-3-3 Proteins: a focus on cancer and human disease. J. Mol. Cell. Cardiol. 37, 633-642 (2004)
72. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42, 801-813 (1993)
73. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ: 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 19, 349-358 (2000)
74. Yin H, Chao L, Chao J: Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad. 14-3-3 signaling pathways. J. Biol. Chem. 280, 8022-8030 (2005)
75. Zaman AK, Fujii S, Goto D, Furumoto T, Mishima T, Nakai Y, Dong J, Imagawa S, Sobel BE, Kitabatake A: Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J. Mol. Cell. Cardiol. 37, 525-535 (2004)